Literature DB >> 16325352

Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation.

Suk-Chul Bae1, Yong Hee Lee.   

Abstract

The RUNX family members play pivotal roles in normal development and neoplasia. RUNX1 and RUNX2 are essential for hematopoiesis and osteogenesis, respectively, while RUNX3 is involved in neurogenesis, thymopoiesis and functions as a tumor suppressor. Inappropriate levels of RUNX activity are associated with leukemia, autoimmune disease, cleidocranial dysplasia, craniosynostosis and various solid tumors. Therefore, RUNX activity must be tightly regulated to prevent tumorigenesis and maintain normal cell differentiation. Recent work indicates that RUNX activity is controlled by various extracellular signaling pathways, and that phosphorylation, acetylation and ubiquitination are important post-translational modifications of RUNX that affect its stability and activity. Defining the precise roles, these modifications that play in the regulation of RUNX function may reveal not only how the RUNX proteins are regulated but also how they are assembled into other regulatory machineries.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325352     DOI: 10.1016/j.gene.2005.10.017

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  52 in total

Review 1.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

2.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

3.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

4.  Prediction of Nepsilon-acetylation on internal lysines implemented in Bayesian Discriminant Method.

Authors:  Ao Li; Yu Xue; Changjiang Jin; Minghui Wang; Xuebiao Yao
Journal:  Biochem Biophys Res Commun       Date:  2006-10-02       Impact factor: 3.575

Review 5.  New insights into the inactivation of gastric tumor suppressor RUNX3: the role of H. pylori infection.

Authors:  Ying-Hung Nicole Tsang; Acacia Lamb; Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

Review 6.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

7.  FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization.

Authors:  Ok-Jin Park; Hyun-Jung Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

8.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

9.  Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells.

Authors:  Gary M Wildey; Philip H Howe
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

10.  Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA.

Authors:  Sanjeev K Baniwal; Omar Khalid; Donna Sir; Grant Buchanan; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Endocrinol       Date:  2009-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.